RenovoRx, Inc. (RNXT) · Nov 20, 2026 · Exec change
Board appointment — Board expanded from six to seven directors
RenovoRx’s board appointment turns a longtime commercial advisor into a director, adding medtech commercialization experience without changing the clinical or financial setup.
RenovoRx is moving from clinical development toward early commercialization of RenovoCath while awaiting Phase III TIGeR-PaC data; by the third quarter of 2026 it had 26 active commercial cancer centers and quarterly revenue above $1 million, while topline trial data remains expected in the second half of 2027.
This is a commercialization-focused governance upgrade, not a change in strategy. The board expanded from six to seven members and appointed Richard Stark, whose background spans medtech sales, oncology, commercialization, fundraising, and strategic transactions. The filing says he had already served as RenovoRx’s Strategic Commercial Advisor since December 2024, so the company is formalizing an existing relationship rather than adding an entirely new operating capability. 〔0〕
The appointment fits the company’s most important near-term challenge: converting physician interest into repeat commercial use. RenovoRx says Stark advised its commercial team for nearly two years and helped build the foundation for commercialization. That matters because the company’s recent progress has been driven by adding centers and increasing utilization, not yet by approved drug revenue or Phase III results. 〔1〕
The economic terms are normal for an outside director and create some dilution, but do not materially alter the business case. Stark received 128,824 ten-year options with a $1.12 exercise price and a $120,000 grant-date fair value, plus a $40,000 annual cash retainer; 12,000 unvested consulting options were forfeited when his prior advisory agreement ended. 〔2〕
Bottom line: This modestly strengthens RenovoRx’s commercialization oversight, but it does not change the core risk-reward setup: execution in the cancer-center rollout and the eventual TIGeR-PaC readout still matter far more than the board seat itself.
TIGeR-PaC topline data, second half of 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!